Last edition
News about Global Pharma
EY Acquires Aqurance to Boost Lifesciences Transformation on Veeva
The acquisition of Aqurance aims to strengthen the EY organisation’s Veeva Centers of Excellence, expanding clinical, regulatory and commercial services capabilities for global pharma and biotech.
Global Pharma | 15/10/2025 | By Dineshwori | 355
EVOQ Therapeutics Receives USD 2 Million NIH Grant to Develop Therapies for Celiac Disease
The NIH award represents a significant endorsement of EVOQ's ground-breaking approach to harnessing the power of the immune system to treat and prevent autoimmune diseases.
Global Pharma | 14/10/2025 | By Dineshwori | 316
Integral Molecular Launches Ready Reporter Virus Kit for 10x Faster Virus Neutralisation Testing
RRVs work by instantaneous detection of viral entry using a fluorescence-based readout. This rapid, safe and simple assay enables automatable workflows that can be performed in a standard laboratory setting.
Global Pharma | 14/10/2025 | By Dineshwori | 147
Cumberland Pharmaceuticals Expands Vibativ Access Through Premier Group Purchasing Agreement
American specialty pharmaceutical company Cumberland Pharmaceuticals has announced that its potent antibiotic Vibativ (telavancin) has been added to a national group purchasing agreement with Premier, a leading US healthcare improvement company.
Global Pharma | 14/10/2025 | By Dineshwori | 275
South Korea's GC Biopharma Secures CMO Rights for Curevo's Shingles Vaccine
South Korean biopharmaceutical company GC Biopharma has signed a contract manufacturing agreement with Curevo Vaccine to produce amezosvatein (development name: CRV-101), a recombinant shingles vaccine currently under clinical development.
Global Pharma | 13/10/2025 | By Dineshwori | 327
The data to be presented span Merck’s broad HIV portfolio, including investigational therapies for both treatment and prevention. The presentations will feature new clinical results from Phase 1, 2, and 3 studies evaluating the efficacy, safety, and pharmacokinetics of the company’s next-generation antiviral candidates.
Global Pharma | 13/10/2025 | By Dineshwori | 324
Chugai Pharma concludes licence agreement with Roche for CT-388
Chugai Pharmaceutical has signed a licensing deal with F. Hoffmann-La Roche for CT-388, a long-acting GLP-1/GIP receptor agonist for obesity and type-II diabetes, granting Chugai exclusive development and marketing rights in Japan.
Global Pharma | 11/10/2025 | By Dineshwori | 721
Johnson & Johnson MedTech Launches CORE-VA Registry to Advance Ventricular Arrhythmia Care
Johnson & Johnson MedTech, in collaboration with the Heart Rhythm Clinical and Research Solutions, has unveiled a new initiative aimed at improving outcomes for patients with life-threatening heart rhythm disorders.
Global Pharma | 11/10/2025 | By Dineshwori | 283
AstraZeneca has announced a historic agreement with President Donald Trump’s administration to lower the cost of prescription medicines for American patients while strengthening the nation’s biopharmaceutical innovation base.
Global Pharma | 11/10/2025 | By Dineshwori | 209
Shuttle Pharmaceuticals Signs LOI to Acquire Molecule.ai in USD 10 Million Deal
US-based specialty pharmaceutical company Shuttle Pharmaceuticals Holdings has signed a non-binding Letter of Intent (LOI) to acquire Molecule.ai, an advanced artificial intelligence firm revolutionising drug discovery and development.
Global Pharma | 10/10/2025 | By Dineshwori | 342
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy